FINWIRES · TerminalLIVE
FINWIRES

Weatherford Tracking Toward Upper End of Q2 Guidance as 2027 Outlook Improves, UBS Says

By

Weatherford International (WFRD) is tracking toward the upper end of its second-quarter guidance with no major surprises from the Middle East conflict, though headwinds are expected to persist into Q3 before a meaningful Q4 recovery and an improving 2027 outlook, UBS Securities said.

The investment firm forecasts Q2 adjusted EBITDA of $213 million and revenue of $1.074 billion versus Street estimates of $209 million and $1.071 billion. The firm also expects adjusted earnings per share of $1.01, above the consensus estimate of $0.92.

Cease-fire progress and the gradual roll-off of startup costs are expected to support a recovery through year-end, according to the note Wednesday.

UBS also sees tightening regional activity after the conflict creating pricing opportunities that could position Weatherford well heading into 2027.

The pending NCS Multistage (NCSM) acquisition adds further upside. The deal expands Weatherford's completions offering, is expected to generate more than $15 million in annual run-rate synergies and could roughly double non-North American revenue contribution over the long term.

UBS maintained its neutral rating and $113 price target.

Price: $84.42, Change: $-0.07, Percent Change: -0.08%

Related Articles

Wire

Arovella Therapeutics Secures Ethics Approval for First-in-Human Study of Blood Cancer Drug Candidate

Arovella Therapeutics (ASX:ALA) received ethics approval from The Alfred and Bellberry Human Research Ethics Committees to begin its phase 1 first-in-human clinical trial of ALA-101 drug candidate, a chimeric antigen receptor invariant natural killer T (CAR-iNKT) cell therapy for patients with relapsed or refractory lymphomas and leukemias, according to a Thursday Australian bourse filing.The trial is expected to involve up to seven clinical sites across Australia and New Zealand, the filing said. It will evaluate the safety, tolerability, and preliminary anti-tumor activity of ALA-101.The company remains on track to begin first patient dosing in the September quarter.Arovella Therapeutics' shares fell past 1% in recent trading on Thursday and earlier hit their lowest since September 2023.

ASX:ALA
Wire

Update: Tourism Holdings Receives Additional Non-Binding Takeover Offer From Unnamed 'Credible Strategic' Buyer; Shares Over Two-Year High

(Updates to add stock movement in the headline and the last paragraph)Tourism Holdings (ASX:THL, NZE:THL) received an additional non-binding indicative offer from an unnamed "credible strategic" buyer to acquire 100% of the company at a proposed price of NZ$3.30 to NZ$3.40 per share, according to a Thursday filing with the New Zealand and Australian bourses.The proposal is subject to customary conditions, including due diligence, board approval, regulatory and third-party consents, and unanimous board recommendation, subject to standard fiduciary carve-outs, per the filing.The company has allowed the bidder to conduct due diligence under a confidentiality agreement while emphasizing that no decision has been made and there is no assurance that a transaction will proceed, the filing said.The company is also engaged in discussions with the BGH consortium on a similar confidentiality agreement to support due diligence, the filing added.The company's shares on the New Zealand bourse rose 12% in Thursday trading and earlier reached their highest level since April 2024, while Australian shares gained 11%.

ASX:THLNZE:THL
Wire

Lockheed Martin Wins Up to $35 Billion Contract to Expand US Missile Defense Production

Lockheed Martin (LMT) won a seven-year US government contract worth up to $35 billion to quadruple production of its Terminal High Altitude Area Defense interceptors.The award is one of the first major multiyear procurement contracts under the Pentagon's new acquisition strategy, Lockheed Martin said Wednesday in a statement.The contract implements a THAAD framework agreement signed in January and is intended to support long-term production scaling and strengthen the missile-defense industrial base for the US and its allies, the company said.Lockheed Martin shares rose 0.9% in after-hours trading.

$LMT